University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Scott C. Kogan, MD

Scott C. Kogan, MD

Professor, Department of Laboratory Medicine, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Research Summary

I am a Professor in the Department of Laboratory Medicine and the Helen Diller Family Comprehenive Cancer Center at the University of California San Francisco. I am a board-certified hematopathologist with 17 years in active practice diagnosing lymphomas, leukemias, and other hematologic disorders. As a past chair of the Hematopathology subcommittee of the National Cancer Institute’s Mouse Models of Human Cancers Consortium, I am an internationally recognized expert in the characteri¬zation and classification of hematopoietic neoplasms in mice as well as in humans. I am also a noted researcher in the molecular pathogenesis of leukemia, including in the role of MYC in hematologic malignancy. My hematopathology training and research background combine to facilitate consultations and collaborations with investigators at UCSF, nationally, and internationally. I use my expertise in the pathology of humans and mice, as well as my experience in clinical pathology/laboratory medicine, to direct the mouse pathology core of the UCSF HDFCCC.

Education

Harvard College, Cambridge, MA, A.B., 1986, Biochemical Sciences
University of California San Francisco, M.D., 1991, Medicine
Laboratory Medicine Residency, UCSF, 1991-1993, Laboratory Medicine
Hematopathology Fellowship, UCSF, 1997-1998, Hematopathology


Professional Experience

  • 1984-1985
    Laboratory of Dr. David Calhoun, Mount Sinai Medical Center, New York City, NY.
  • 1985-1986
    Laboratory of Dr. Leonard Guarente, Massachusetts Institute of Technology, Cambridge, MA.
  • 1986-1991
    Laboratory of Dr. Jane Gitschier, Howard Hughes Medical Institute of California, UCSF
  • 1991-1992
    Resident, Department of Laboratory Medicine, UCSF
  • 1992-1993
    Chief Resident, Department of Laboratory Medicine, UCSF
  • 1993-1997
    Laboratory of Dr. J. Michael Bishop, G.W. Hooper Foundation, UCSF
  • 1997-1998
    Hematopathology Fellow, Department of Laboratory Medicine, UCSF
  • 1998-2003
    Assistant Professor In-Residence, Department of Laboratory Medicine, UCSF
  • 2003-2008
    Associate Professor In-Residence, Department of Laboratory Medicine, UCSF
  • 2008-present
    Professor, Department of Laboratory Medicine, UCSF
  • 2000-2004
    Chair, Hematopathology Subcommittee, Mouse Models of Human Cancer Consortium, NCI
  • 2001-present
    Co-director, Mouse Pathology Shared Resource, UCSF Comprehensive Cancer Center
  • 2004-2007
    Member Scientific Committee Clinical Laboratory Hematology, American Society of Hematology
  • 2008-2009
    Chair Scientific Committee Hematopathology & Clinical Laboratory Hematology, ASH

Honors & Awards

  • 1986
    Summa Cum Laude, Phi Beta Kappa
  • 1986
    Joseph L. Barrett Award for Teaching, Harvard University
  • 1993
    National Committee for Clinical Laboratory Standards, Honored Graduate Award
  • 1993
    UCSF Molecular Medicine Training Program
  • 1993
    American Cancer Society Physician Research Training Award
  • 1994
    Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians
  • 1997
    Burroughs Wellcome Fund Career Award
  • 2000
    32nd Edward Mallinckrodt Jr. Scholar Award
  • 2001
    Medical Student Teaching Award, Excellence for Small Group Instruction
  • 2002
    Department of Laboratory Medicine Resident Teaching Award
  • 2004
    Leukemia & Lymphoma Society Scholar Award
  • 2007
    Mentor Award, UCSF Department of Pediatrics

Selected Publications

  1. Nielsen AB, Zhou M, de Smith AJ, Wang R, McCoy L, Hansen H, Morimoto L, Grønbæk K, Johansen C, Kogan SC, Metayer C, Bracci PM, Ma X, Wiemels JL. Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in etiology. Haematologica. 2019 03 28.
    View on PubMed
  2. Esnault C, Rahmé R, Rice KL, Berthier C, Gaillard C, Quentin S, Maubert AL, Kogan S, de Thé H. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. Blood. 2019 Mar 28; 133(13):1495-1506.
    View on PubMed
  3. Gaillard C, Surianarayanan S, Bentley T, Warr MR, Fitch B, Geng H, Passegué E, de Thé H, Kogan SC. Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia. Blood Adv. 2018 Oct 09; 2(19):2462-2466.
    View on PubMed
  4. Jacquot C, Wool GD, Kogan SC. Dilute Russell viper venom time interpretation and clinical correlation: A two-year retrospective institutional review. Int J Lab Hematol. 2019 Feb; 41(1):80-86.
    View on PubMed
  5. Yang T, Cui H, Wen M, Zuber J, Kogan SC, Wei G. TCEA1 regulates the proliferative potential of mouse myeloid cells. Exp Cell Res. 2018 Sep 15; 370(2):551-560.
    View on PubMed
  6. Fuqua BK, Lu Y, Frazer DM, Darshan D, Wilkins SJ, Dunn L, Loguinov AV, Kogan SC, Matak P, Chen H, Dunaief JL, Vulpe CD, Anderson GJ. Severe Iron Metabolism Defects in Mice With Double Knockout of the Multicopper Ferroxidases Hephaestin and Ceruloplasmin. Cell Mol Gastroenterol Hepatol. 2018; 6(4):405-427.
    View on PubMed
  7. An S, Wang X, Ruck MA, Rodriguez HJ, Kostyushev DS, Varga M, Luu E, Derakhshandeh R, Suchkov SV, Kogan SC, Hermiston ML, Springer ML. Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes. Mol Ther. 2018 07 05; 26(7):1685-1693.
    View on PubMed
  8. Lehmann-Che J, Bally C, Letouzé E, Berthier C, Yuan H, Jollivet F, Ades L, Cassinat B, Hirsch P, Pigneux A, Mozziconacci MJ, Kogan S, Fenaux P, de Thé H. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nat Commun. 2018 05 24; 9(1):2047.
    View on PubMed
  9. Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave CJ, Hills RK, Salomoni P, Kogan SC, Solomon E, Grimwade D. Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice. Blood. 2018 02 08; 131(6):636-648.
    View on PubMed
  10. Foley N, Van Ziffle J, Yu J, Qi Z, Grenert JP, Yeh I, Bastian B, Kogan S, Mannis GN. Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation? Cancer Genet. 2017 Oct; 216-217:74-78.
    View on PubMed
  11. Francis SS, Wallace AD, Wendt GA, Li L, Liu F, Riley LW, Kogan S, Walsh KM, de Smith AJ, Dahl GV, Ma X, Delwart E, Metayer C, Wiemels JL. In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia. Blood. 2017 03 23; 129(12):1680-1684.
    View on PubMed
  12. Keeshan K, Vieugué P, Chaudhury S, Rishi L, Gaillard C, Liang L, Garcia E, Nakamura T, Omidvar N, Kogan SC. Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPa as a common target of TRIB1 and PML/RARA. Haematologica. 2016 10; 101(10):1228-1236.
    View on PubMed
  13. Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, Gore SD, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Le Beau MM, Kogan S, Salomonis N, Figueroa ME, Grimes HL. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discov. 2016 05; 6(5):501-15.
    View on PubMed
  14. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2016 Jan; 126(1):404.
    View on PubMed
  15. Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 2015 Jul 20; 4.
    View on PubMed
  16. Gaillard C, Tokuyasu TA, Rosen G, Sotzen J, Vitaliano-Prunier A, Roy R, Passegué E, de Thé H, Figueroa ME, Kogan SC. Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation. Haematologica. 2015 Aug; 100(8):1064-75.
    View on PubMed
  17. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015 Jul; 16(7):766-774.
    View on PubMed
  18. Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, Kogan SC. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol. 2015 Jul; 76(1):35-46.
    View on PubMed
  19. Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet. 2015 May; 47(5):539-43.
    View on PubMed
  20. Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014 Dec 18; 124(26):3947-55.
    View on PubMed

Go to UCSF Profiles, powered by CTSI